Cargando…

Reduced risk of clinically important deteriorations by ICS in COPD is eosinophil dependent: a pooled post-hoc analysis

BACKGROUND: Clinically Important Deterioration (CID) is a novel composite measure to assess treatment effect in chronic obstructive pulmonary disease (COPD). We examined the performance and utility of CID in assessing the effect of inhaled corticosteroids (ICS) in COPD. METHODS: This post-hoc analys...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bafadhel, Mona, Singh, Dave, Jenkins, Christine, Peterson, Stefan, Bengtsson, Thomas, Wessman, Peter, Fagerås, Malin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6954504/ https://www.ncbi.nlm.nih.gov/pubmed/31924197 http://dx.doi.org/10.1186/s12931-020-1280-y

Ejemplares similares

Benefits of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate on COPD Exacerbations, Lung Function, Symptoms, and Quality of Life Across Blood Eosinophil Ranges: A Post-Hoc Analysis of Data from ETHOS
por: Bafadhel, Mona, et al.
Publicado: (2022)

Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA
por: Singh, Dave, et al.
Publicado: (2019)

Eosinophilic inflammation in COPD: from an inflammatory marker to a treatable trait
por: David, Benjamin, et al.
Publicado: (2021)

Tiotropium/Olodaterol Delays Clinically Important Deterioration Compared with Tiotropium Monotherapy in Patients with Early COPD: a Post Hoc Analysis of the TONADO(®) Trials
por: Rabe, Klaus F., et al.
Publicado: (2020)

Shall We Focus on the Eosinophil to Guide Treatment with Systemic Corticosteroids during Acute Exacerbations of COPD?: PRO
por: Camp, James, et al.
Publicado: (2018)

When to Use Initial Triple Therapy in COPD: Adding a LAMA to ICS/LABA by Clinically Important Deterioration Assessment
por: Cheng, Wen-Chien, et al.
Publicado: (2020)

Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol
por: Singh, Dave, et al.
Publicado: (2016)

COPD exacerbation severity and frequency is associated with impaired macrophage efferocytosis of eosinophils
por: Eltboli, Osama, et al.
Publicado: (2014)

Comparison of glycopyrronium versus tiotropium on the time to clinically important deteriorations in patients with COPD: a post-hoc analysis of randomized trials
por: D’Urzo, Anthony, et al.
Publicado: (2018)

Measuring disease activity in COPD: is clinically important deterioration the answer?
por: Singh, Dave, et al.
Publicado: (2020)

Mepolizumab for Eosinophil-Associated COPD: Analysis of METREX and METREO
por: Pavord, Ian D, et al.
Publicado: (2021)

Composite endpoints in COPD: clinically important deterioration in the UPLIFT trial
por: Rabe, Klaus F., et al.
Publicado: (2020)

Blood eosinophils to guide inhaled maintenance therapy in a primary care COPD population
por: Ashdown, Helen F., et al.
Publicado: (2021)

Prognostic value of clinically important deterioration in COPD: IMPACT trial analysis
por: Han, MeiLan K., et al.
Publicado: (2021)

Correction to: Measuring disease activity in COPD: is clinically important deterioration the answer?
por: Singh, Dave, et al.
Publicado: (2021)

Clinically Important Deterioration Among Patients with Chronic Obstructive Pulmonary Disease (COPD) Treated with Nebulized Glycopyrrolate: A Post Hoc Analysis of Pooled Data from Two Randomized, Double-Blind, Placebo-Controlled Studies
por: Kerwin, Edward M, et al.
Publicado: (2020)

Preventing Clinically Important Deterioration of COPD with Addition of Umeclidinium to Inhaled Corticosteroid/Long-Acting β(2)-Agonist Therapy: An Integrated Post Hoc Analysis
por: Naya, Ian P., et al.
Publicado: (2018)

Early efficacy of budesonide/formoterol in patients with moderate-to-very-severe COPD
por: Calverley, Peter M, et al.
Publicado: (2016)

Blood Eosinophils in Chinese COPD Participants and Response to Treatment with Combination Low-Dose Theophylline and Prednisone: A Post-Hoc Analysis of the TASCS Trial
por: Bradbury, Thomas, et al.
Publicado: (2022)

The effect of COPD severity and study duration on exacerbation outcome in randomized controlled trials
por: Eriksson, Göran, et al.
Publicado: (2017)

Eosinophilic inflammation, coronavirus disease 2019, and asthma: Are inhaled corticosteroids the missing link?
por: Ramakrishnan, Sanjay, et al.
Publicado: (2021)

Evaluation of Budesonide-Formoterol for Maintenance and Reliever Therapy Among Patients With Poorly Controlled Asthma: A Systematic Review and Meta-analysis
por: Beasley, Richard, et al.
Publicado: (2022)

Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study
por: Greulich, Timm, et al.
Publicado: (2018)

ICS and COPD: Time to clear the air
por: Ford, Paul A, et al.
Publicado: (2009)

Blood eosinophils as a biomarker of future COPD exacerbation risk: pooled data from 11 clinical trials
por: Singh, Dave, et al.
Publicado: (2020)

Renaming COPD exacerbations: the UK respiratory nursing perspective
por: Mwasuku, Christine, et al.
Publicado: (2021)

Comparison of the peripheral blood eosinophil count using near-patient testing and standard automated laboratory measurement in healthy, asthmatic and COPD subjects
por: Hambleton, Kirsty, et al.
Publicado: (2017)

Preventing clinically important deterioration with single-inhaler triple therapy in COPD
por: Naya, Ian, et al.
Publicado: (2018)

Predictive modeling of COPD exacerbation rates using baseline risk factors
por: Singh, Dave, et al.
Publicado: (2022)

COPD exacerbations and patient-reported outcomes according to post-bronchodilator FEV(1) – a post-hoc analysis of pooled data
por: Chai, Chee-Shee, et al.
Publicado: (2023)

Overcoming Therapeutic Inertia to Reduce the Risk of COPD Exacerbations: Four Action Points for Healthcare Professionals
por: Singh, Dave, et al.
Publicado: (2021)

Benralizumab Prevents Recurrent Exacerbations in Patients with Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis
por: Singh, Dave, et al.
Publicado: (2023)

Treatment response to indacaterol/glycopyrronium versus salmeterol/fluticasone in exacerbating COPD patients by gender: a post-hoc analysis in the FLAME study
por: Wedzicha, Jadwiga A., et al.
Publicado: (2019)

Assessing Short-term Deterioration in Maintenance-naïve Patients with COPD Receiving Umeclidinium/Vilanterol and Tiotropium: A Pooled Analysis of Three Randomized Trials
por: Maleki-Yazdi, M. Reza, et al.
Publicado: (2016)

Asthma control with ICS-formoterol reliever versus maintenance ICS and SABA reliever therapy: a post hoc analysis of two randomised controlled trials
por: Hatter, Lee, et al.
Publicado: (2022)

Clinical characteristics of eosinophilic COPD versus COPD patients with a history of asthma
por: Kolsum, Umme, et al.
Publicado: (2017)

Comparison of Characteristics Between ICS-Treated COPD Patients and ICS-Treated COPD Patients with Concomitant Asthma: A Study in Primary Care
por: Savran, Osman, et al.
Publicado: (2020)

Long-term outcomes following first short-term clinically important deterioration in COPD
por: Naya, Ian P., et al.
Publicado: (2018)

Exhaled nitric oxide, eosinophils and current smoking in COPD patients
por: Higham, Andrew, et al.
Publicado: (2023)

Deterioration of lung function and its association with eosinophil count
por: Rajanayagam, Bama, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_p1rcn09tbrp9e6ifh830k0m754